GABRB1

Across TCGA pan-cancer cohorts, GABRB1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GABRB1 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher GABRB1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GABRB1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and LUAD are the cancer types where GABRB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	II,III,IV	0.010	0.632	<.001	33	view →
UCEC	DFS	Median	All	0.953	0.618	.004	32	view →
LUAD	OS	Median	II,III,IV	0.353	0.722	<.001	30	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	12	view →
LIHC	OS	Median	All	0.255	0.773	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GABRB1–ACC (DFS)

Open the ACC breakdown →